Emergence of lamivudine-resistant HBV during antiretroviral therapy including lamivudine for patients coinfected with HIV and HBV in China

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Gu, Lijun ^a,b   Han, Yang ^c   Li, Yijia ^c   Zhu, Ting ^c   Song, Xiaojing ^c   Huang, Ying ^a   Yang, Feifei ^a   Guan, Shuo ^a   Xie, Jing ^c   Gohda, Jin ^a,b   Hosoya, Noriaki ^b   Kawana Tachikawa, Ai ^b   Liu, Wenjun ^a   Gao, George Fu ^a   Iwamoto, Aikichi ^b   Li, Taisheng ^c   Ishida, Takaomi ^a,b  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF TOKYO   (Japan)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHINA; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MIXED INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; VIRUS LOAD; ADOLESCENT; CLINICAL TRIAL; COINFECTION; DRUG EFFECTS; HIV INFECTIONS; MIDDLE AGED; PHYSIOLOGY; VIRUS REPLICATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CHINA; COINFECTION; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; VIRUS REPLICATION; YOUNG ADULT;

EID: 84942626763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134539     Document Type: Article

References (35)

1. WHO Library Cataloguing-in-Publication Data, Global report: UNAIDS report on the global AIDS epidemic 2012. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-with-Annexes-en.pdf.
2. WHO Library Cataloguing-in-Publication Data, Global policy report on the prevention and control of viral hepatitis in WHO Member States. Available: http://apps.who.int/iris/bitstream/10665/85397/1/9789241564632-eng.pdf.
3. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ(2012) HIV-HBV coinfection-A global challenge. N Engl J Med 366: 1749-1752. doi:10.1056/NEJMp1201796 PMID: 22571198
4. Thio CL, Smeaton L, Saulynas M, Hwang H, Saravanan S, Kulkarni S, et al.(2013) Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS 27: 191-201. doi:10.1097/QAD. 0b013e32835a9984 PMID: 23032418
5. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available: http://aidsinfo.nih.gov/guidelines.
6. WHO Library Cataloguing-in-Publication Data. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2006 revision. Available: http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf?ua=1.
7. Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, et al.(1995) Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345: 396-397. PMID: 7845151
8. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al.(2013) Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 21: 6-14. PMID: 23596273
9. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al.(2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6: 531-561. doi:10. 1007/s12072-012-9365-4 PMID: 26201469
10. Iser DM, Sasadeusz JJ(2008) Current treatment of HIV/hepatitis B virus coinfection. J Gastroenterol Hepatol 23: 699-706. doi:10.1111/j.1440-1746.2008.05382.x PMID: 18410604
11. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al.(2006) Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20: 863-870. PMID: 16549970
12. Childs K, Joshi D, Byrne R, Bruce M, Carey I, Agarwal K, et al.(2013) Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia. AIDS 27: 1443-1448. doi:10.1097/QAD.0b013e32836011c2 PMID: 23435302
13. Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, et al.(2013) Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 56: e87-e94. doi:10.1093/cid/cit002 PMID: 23315316
14. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al.(2013) Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-Analysis. PLoS One 8: e68152. doi:10.1371/journal.pone.0068152 PMID: 23874527
15. Uniting the world against AIDS in China. Available: http://www.unaids.org.cn/en/index/page.asp?id= 197& class=2& classname=China%E2%80%99s+Epidemic+%26+Response+.
16. Wang H, Li Y, Zhang C, Han Y, Zhang X, Zhu T, et al.(2012) Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. AIDS 26: 1755-1763. PMID: 22614885
17. Li T, Dai Y, Kuang J, Jiang J, Han Y, Qiu Z, et al.(2008) Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. PLoS One 3: e3918. doi:10. 1371/journal.pone.0003918 PMID: 19081791
18. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D'Acunto K, Phair J, et al.(2009) Hepatitis B and longterm HIV outcomes in coinfected HAART recipients. AIDS 23: 1881-1889. doi:10.1097/QAD. 0b013e32832e463a PMID: 19550291
19. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al.(1999) Long-Term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30: 1302-1306. PMID: 10534354
20. Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC(2014) Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World J Gastroenterol 20: 14598-14614. doi:10.3748/wjg.v20.i40.14598 PMID: 25356024
21. Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Miailhes P, et al.(2013) High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology 58: 912-922. doi:10.1002/hep.26374 PMID: 23468093
22. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al.(1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27: 1670-1677. PMID: 9620341
23. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al.(2007) Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46: 254-265. PMID: 17596850
24. Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K(2009) Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 19: 165-176. PMID: 19374144
25. Lin CL, Kao JK(2011) The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 26 Suppl 1: 123-130. doi:10.1111/j.1440-1746.2010.06541.x PMID: 21199523
26. Croagh CM, Desmond PV, Bell SJ(2015) Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World J Hepatol 7: 289-303. doi:10.4254/wjh.v7.i3.289 PMID: 25848459
27. Hua W, Zhang G, Guo S, Li W, Sun L, Xiang G(2015) Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection. Braz J Infect Dis 19: 291-295. doi:10.1016/j.bjid.2015.03.012 PMID: 25982306
28. Cui Y, Jia J(2013) Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol 28 Suppl 1: 7-10. doi:10.1111/jgh.12220 PMID: 23855289
29. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF(2003) Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38: 1267-1273. PMID: 14578866
30. Akuta N, Kumada H(2005) Influence of hepatitis B virus genotypes on the response to antiviral therapies. J Antimicrob Chemother 55: 139-142. PMID: 15618285
31. Chu CM, Liaw YF(2005) Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 43: 411-417. PMID: 16006001
32. Zhang FJ. Handbook of national free antiretroviral treatment of AIDS. 3rd Ed. Beijing: People's Medical Publishing House. 2012. p 41. Chinese.
33. Hsiang JC, Wong GL, Chan HL, Chan AW, Chim AM, Wong VW(2014) Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Aliment Pharmacol Ther 40: 716-726. doi:10.1111/apt.12874 PMID: 25039861
34. Burns GS, Thompson AJ(2014) Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med 4: a024935. doi:10.1101/cshperspect.a024935 PMID: 25359547
35. Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, et al.(2012) Fiveyear on-Treatment efficacy of lamivudine-, tenofovir-And tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat 19: 801-810. doi:10.1111/j.1365-2893.2012.01601.x PMID: 23043387